Peritoneal Cavity Cancer Clinical Trial
Official title:
Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study
Phase II multicentric study
The aim of this prospective Phase II multicentric study is to assess feasibility and early complications rate of "total laparoscopic/robotic" interval debulking surgery in patients with a clinical complete/partial response to neoadjuvant chemotherapy for advanced ovarian cancer. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00702299 -
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT00003896 -
S9912 Combination Chemo in Stage III Ovarian Cancer,
|
Phase 2 | |
| Completed |
NCT00003450 -
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT00010179 -
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
|
Phase 2 | |
| Completed |
NCT00625092 -
Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
|
Phase 1 | |
| Terminated |
NCT00331422 -
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
|
Phase 2 | |
| Completed |
NCT00101257 -
Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT00004895 -
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT00030706 -
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
|
Phase 2 | |
| Completed |
NCT00003120 -
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
|
Phase 3 | |
| Completed |
NCT00803569 -
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
|
Phase 1 | |
| Completed |
NCT00466960 -
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
|
Phase 2 | |
| Completed |
NCT00217568 -
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
|
Phase 2 | |
| Terminated |
NCT00653328 -
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT00005049 -
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
|
Phase 2 | |
| Completed |
NCT00993655 -
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01670799 -
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
Early Phase 1 | |
| Terminated |
NCT01096381 -
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
|
N/A | |
| Terminated |
NCT00652899 -
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
|
Phase 2 | |
| Completed |
NCT00436644 -
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
|
Phase 2 |